CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...